C. Nicholson
Director/Board Member at ADVERUM BIOTECHNOLOGIES, INC.
Net worth: 2 607 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steve O'Loughlin | M | 39 | 9 years | |
Laurent Fischer | M | 60 | 8 years | |
Ben Taylor | M | 46 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 4 years |
Elizabeth Crain | F | 59 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 3 years |
Sandesh Seth | M | 60 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 12 years |
Andrew Hopkins | M | 52 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 12 years |
Daniel John Knox | M | - |
Science Exchange, Inc.
Science Exchange, Inc. Internet Software/ServicesTechnology Services Science Exchange, Inc. operates an online marketplace for outsourcing science experiments. The firm is a community marketplace for scientists to list, discover access, and pay for scientific services from institutions around the world. The company was founded by Elizabeth Iorns, Ryan Abbott and Daniel John Knox in 2011 and is headquartered in San Francisco, CA. | 13 years |
Elizabeth Iorns | M | - |
Science Exchange, Inc.
Science Exchange, Inc. Internet Software/ServicesTechnology Services Science Exchange, Inc. operates an online marketplace for outsourcing science experiments. The firm is a community marketplace for scientists to list, discover access, and pay for scientific services from institutions around the world. The company was founded by Elizabeth Iorns, Ryan Abbott and Daniel John Knox in 2011 and is headquartered in San Francisco, CA. | 13 years |
Sushant Kumar | M | - |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | - |
Sandra Peterson | F | 65 |
Bayer CropScience AG
Bayer CropScience AG Chemicals: AgriculturalProcess Industries Bayer CropScience AG manufactures and distributes pesticides, and vegetable seeds. Its products include crops such as cotton, fruits and vegetables, oil seeds and wheat, brands includes fungicides, herbicides and seeds growth. The company was founded in 1979 and is headquartered In Monheim am Rhein, Germany.
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | 8 years |
Dawn Svoronos | F | 70 | 7 years | |
Clarence Machado | M | 60 | 7 years | |
Peter Soparkar | M | 53 | 5 years | |
Chirfi Guindo | M | 58 | 13 years | |
Sara Blum Sherman | F | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 3 years |
Rabia Ozden | M | 56 | 2 years | |
Jeffrey Chell | M | 70 | 6 years | |
Avinash Desai | M | - | 4 years | |
Samuel Bakhoum | M | - |
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | - |
Heikki Jouttijärvi | M | - | 4 years | |
Robert Michael | M | 53 | 4 years | |
Joanne Xu | F | 46 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 3 years |
Garry Pairaudeau | M | 58 |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 4 years |
Amanda Galgay | F | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | 2 years |
Dalton Smart | M | 58 | 15 years | |
Soo Hong | F | 52 | 2 years | |
Anand Reddi | M | 42 | - | |
Janice Chang | F | - |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | 10 years |
Ross Hendron | M | - |
WILD BIOSCIENCE LTD
WILD BIOSCIENCE LTD Miscellaneous Commercial ServicesCommercial Services Wild Bioscience Ltd. is a British crop improvement company that specializes in providing carbon mitigation, yield enhancement, and farm productivity solutions. The company is based in Abingdon, UK. It was founded in 2021 by Ross Hendron and Steven Bryan Kelly, with Ross Hendron serving as the CEO since 2021. | 3 years |
Richard Steinhart | M | 66 | 11 years | |
Scott Michael Whitcup | M | 64 | 4 years | |
Steven Kelly | M | - |
WILD BIOSCIENCE LTD
WILD BIOSCIENCE LTD Miscellaneous Commercial ServicesCommercial Services Wild Bioscience Ltd. is a British crop improvement company that specializes in providing carbon mitigation, yield enhancement, and farm productivity solutions. The company is based in Abingdon, UK. It was founded in 2021 by Ross Hendron and Steven Bryan Kelly, with Ross Hendron serving as the CEO since 2021. | 3 years |
Ajit Shetty | M | 77 | 7 years | |
Mark Lupher | M | 53 | 5 years | |
Jim Scopa | M | 65 | 5 years | |
Reed Tuckson | M | 73 | 3 years | |
Charles Hugh-Jones | M | - |
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | 3 years |
David Epstein | M | 62 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 4 years |
Peter Molloy | M | 52 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | - |
John Rakow | M | 67 | 3 years | |
Paolo Pucci | M | 63 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 4 years |
Robert Glassman | M | 62 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | 3 years |
Carlos J. Barroso | M | 65 |
Science Exchange, Inc.
Science Exchange, Inc. Internet Software/ServicesTechnology Services Science Exchange, Inc. operates an online marketplace for outsourcing science experiments. The firm is a community marketplace for scientists to list, discover access, and pay for scientific services from institutions around the world. The company was founded by Elizabeth Iorns, Ryan Abbott and Daniel John Knox in 2011 and is headquartered in San Francisco, CA. | 6 years |
Linda Rubinstein | F | 58 | 2 years | |
Shaun O'Connor | M | - |
Science Exchange, Inc.
Science Exchange, Inc. Internet Software/ServicesTechnology Services Science Exchange, Inc. operates an online marketplace for outsourcing science experiments. The firm is a community marketplace for scientists to list, discover access, and pay for scientific services from institutions around the world. The company was founded by Elizabeth Iorns, Ryan Abbott and Daniel John Knox in 2011 and is headquartered in San Francisco, CA. | 7 years |
Bill Tan | M | - | 3 years | |
Jenny Hsieh | F | - | - | |
Kathryn Owen | F | - |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | - |
Steven Gilman | M | 71 |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | - |
Star Seyedkazemi | M | 50 | 2 years | |
Amy Schulman | F | 63 |
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | - |
Sanat Chattopadhyay | M | - | 15 years | |
Brian Daniels | M | 65 |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | - |
Romuald Corbau | M | 55 | - | |
Zafrira Avnur | M | 73 |
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | - |
Scott Reents | M | - | 4 years | |
Dena House | F | - | 5 years | |
Richard DeLuca | M | 61 | 13 years | |
Carla Fiankan | F | - | - | |
Denise Williams | F | - | 15 years | |
Pamela Eisele | F | - | 15 years | |
Caroline Rowland | F | - | 2 years | |
R. Ramelmeier | M | 62 | 1 years | |
Luc Dochez | M | 49 |
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | - |
Takuko Yamada-Sawada | F | - |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | 10 years |
Ryan Quigley | M | - | 4 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Sergio Traversa | M | 63 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 5 years |
Dragan Cicic | M | 60 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 12 years |
Kaushik J. Dave | M | 63 | 4 years | |
Scott Giacobello | M | 54 | 7 years | |
Brenton Saunders | M | 56 | 6 years | |
Paul Bisaro | M | 63 | 5 years | |
Richard Clark | M | 77 | 6 years | |
John V. Talley | M | 68 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 1 years |
David Adam Buchen | M | 59 | 1 years | |
Diane S. Button | F | 73 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 6 years |
James D'Arecca | M | 53 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 15 years |
Fred Hassan | M | 78 | 6 years | |
David Parry | M | 70 |
The University of Manchester
| 7 years |
Julie Gerberding | M | 69 | - | |
John Kelly | M | 57 | 6 years | |
Christopher Coughlin | M | 71 | 6 years | |
Fung Man Wai | M | 75 |
The University of Manchester
| 4 years |
Jean-Marie Canan | M | 68 | 5 years | |
Roger J. Lias | M | 63 | 6 years | |
Ambrose Bailey | M | 60 | 6 years | |
Thomas Robert Cech | M | 76 | - | |
Roger Aston | M | 68 |
The University of Manchester
| 6 years |
Hafrun Fridriksdottir | M | 62 | 14 years | |
John A. King | M | 74 | 2 years | |
Tamar Howson | F | 75 | 9 years | |
Fred G. Weiss | M | 82 | 18 years | |
Catherine Klema | F | 65 | 15 years | |
Harry R. Jacobson | M | 76 | 3 years | |
William N. Kelley | M | 84 | - | |
Patrick O’Sullivan | M | 82 | 5 years | |
Caroline Dorsa | F | 64 | 22 years | |
Carlos Eduardo Represas de Almeida | M | 78 | - | |
Christopher Bodine | M | 68 | 11 years | |
Michael Nally | M | 48 | 10 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 69 | 69.00% |
Ireland | 21 | 21.00% |
United Kingdom | 10 | 10.00% |
Israel | 3 | 3.00% |
Germany | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- C. Nicholson
- Personal Network